PLSE

PLSE

USD

Pulse Biosciences Inc Common Stock (DE)

$16.060-0.440 (-2.667%)

Preço em tempo real

Healthcare
Medical Instruments & Supplies
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$16.500

Máximo

$16.770

Mínimo

$15.800

Volume

0.11M

Fundamentos da empresa

Capitalização de mercado

1.1B

Setor

Medical Instruments & Supplies

País

United States

Estatísticas de negociação

Volume médio

0.18M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $13.766Atual $16.060Máximo $25

Notícias relacionadas

BusinessWire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Ver mais
Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study
BusinessWire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it

Ver mais
Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025
BusinessWire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology

Ver mais
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting
BusinessWire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced

Ver mais
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.